Please login to the form below

Not currently logged in
Email:
Password:

HAE

This page shows the latest HAE news and features for those working in and with pharma, biotech and healthcare.

Shire claims US okay for HAE blockbuster-in-waiting

Shire claims US okay for HAE blockbuster-in-waiting

Shire claims US okay for HAE blockbuster-in-waiting. FDA approves Takhzyro as a preventative measure for HAE attacks. ... Takhzyro provides the HAE community with a new option for the prevention of HAE attacks, ”he added.

Latest news

  • Immunology keeps Shire figures solid as Takeda takeover nears Immunology keeps Shire figures solid as Takeda takeover nears

    Shire recently picked up additional approvals for Vonvendi/Veyvondi for von Willebrand disease and its hereditary angioedema (HAE) therapy Cinryze and has three new therapies filed for approval, namely lanadelumab for ... HAE, prucalopride (SHP555) for

  • EMA starts rapid review of Shire’s HAE antibody EMA starts rapid review of Shire’s HAE antibody

    two weeks resulted in an 87% reduction in the mean frequency of HAE attacks overall, according to Shire. ... Other approved treatments for HAE include CSL Behring’s Berinert and Pharming’s Ruconest.

  • Shire completes $32bn Baxalta merger Shire completes $32bn Baxalta merger

    The pipeline will focus on therapy areas including haematology, immunology, neuroscience, lysosmal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE), and brings Baxalta's haemophilia franchise into the fold.

  • Baxalta agrees to $32bn Shire takeover Baxalta agrees to $32bn Shire takeover

    disease therapies across haematology, immunology, neuroscience, lysosomal storage disorders, gastrointestinal/endocrine and disease and hereditary angioedema (HAE). ... drugs such as its HAE therapy Cinryze (C1 esterase inhibitor) and Natpara

  • Shire deal with Baxalta predicted this week Shire deal with Baxalta predicted this week

    HAE) therapy DX-2930 - and a $5.2bn purchase of NPS Pharma which gave it control of Natpara (recombinant parathyroid hormone) for hypoparathyroidism.

More from news
Approximately 3 fully matching, plus 22 partially matching documents found.

Latest Intelligence

  • A rare talent A rare talent

    and HAE.”.

  • Deal Watch November 2015 Deal Watch November 2015

    Given that Shire's Cinryze is already approved in HAE, It will be interesting to see what the regulators say on the anti-competition front. ... 160, 000. Dyax Corporation. Shire. Acquisition - company. Includes KALBITOR marketed for acute attacks of HAE

More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest appointments

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Star

We're passionate about helping our clients to make a real commercial impact. We achieve this through our unique approach to...

Latest intelligence

image 1
Redefining communications excellence
How to be heard in today’s multichannel, multistakeholder, multimedia world...
AZ Campus
AstraZeneca: building a new ‘open innovation’ pharma company
The construction of its new HQ has suffered some serious delays, but new R&D and commercial success are lifting AstraZeneca’s prospects...
Erik Nordkamp
In conversation with Pfizer’s Erik Nordkamp
Pfizer’s UK general manager talks to PME about the NHS at 70, the potential of pharma partnerships and some lessons from Europe...

Infographics